Parnell Pharmaceuticals Holdings (NASDAQ: PARN) and Flexion Therapeutics (NASDAQ:FLXN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitabiliy, analyst recommendations, institutional ownership, dividends, risk, earnings and valuation.
This table compares Parnell Pharmaceuticals Holdings and Flexion Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Parnell Pharmaceuticals Holdings||-130.46%||-83.86%||-43.24%|
Risk & Volatility
Parnell Pharmaceuticals Holdings has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Comparatively, Flexion Therapeutics has a beta of 1.16, suggesting that its stock price is 16% more volatile than the S&P 500.
This is a summary of recent recommendations and price targets for Parnell Pharmaceuticals Holdings and Flexion Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Parnell Pharmaceuticals Holdings||0||0||0||0||N/A|
Flexion Therapeutics has a consensus target price of $31.56, suggesting a potential upside of 83.48%. Given Flexion Therapeutics’ higher possible upside, analysts clearly believe Flexion Therapeutics is more favorable than Parnell Pharmaceuticals Holdings.
Institutional & Insider Ownership
16.9% of Parnell Pharmaceuticals Holdings shares are owned by institutional investors. Comparatively, 75.6% of Flexion Therapeutics shares are owned by institutional investors. 18.0% of Flexion Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Earnings & Valuation
This table compares Parnell Pharmaceuticals Holdings and Flexion Therapeutics’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Parnell Pharmaceuticals Holdings||N/A||N/A||N/A||N/A||N/A|
|Flexion Therapeutics||N/A||N/A||-$75.25 million||($2.81)||-6.12|
Flexion Therapeutics beats Parnell Pharmaceuticals Holdings on 9 of the 9 factors compared between the two stocks.
About Parnell Pharmaceuticals Holdings
Parnell Pharmaceuticals Holdings Limited is a veterinary pharmaceutical company. The Company is focused on developing, manufacturing and commercializing animal health solutions. The principal activities of the Company include manufacture for global sale of animal pharmaceutical product, and research and development of pharmaceutical products for global animal health markets. The Company operates through four segments: Companion Animal, Production Animal-U.S., Production Animal-Rest of World and Manufacturing Operations. It augments its pharmaceutical products with its FETCH and mySYNCH software platforms. It offers disease-modifying product, Zydax, for the treatment of osteoarthritis (OA). Its reproductive hormone products include estroPLAN and GONAbreed. It has a nutraceutical product, Glyde. It also markets a non-steroidal anti-inflammatory drug (NSAID), called Tergive. It is developing a pipeline of clinical drug candidates, such as PAR 121, PAR 122, PAR 101, PAR 081 and PAR 061.
About Flexion Therapeutics
Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid. The Company is developing Zilretta as a treatment for patients with moderate to severe OA knee pain. The Company has specifically designed Zilretta to combine a steroid, triamcinolone acetonide (TCA) with poly lactic-co-glycolic acid (PLGA), for providing sustained therapeutic concentrations in the joint and persistent analgesic effect. The Company’s other product candidates include FX007 for post-operative pain and FX005 for the treatment of end-stage OA patients. The Company is engaged in conducting a Phase IIb clinical trial of Zilretta.
Receive News & Ratings for Parnell Pharmaceuticals Holdings Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Parnell Pharmaceuticals Holdings Ltd and related companies with MarketBeat.com's FREE daily email newsletter.